Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?

Coombes, Ian D; Legg, Amy; Patterson, Tina; Kelly, Tanya; Henderson, Andrew; Roberts, Jason A

Coombes, Ian D; Legg, Amy; Patterson, Tina; Kelly, Tanya; Henderson, Andrew; Roberts, Jason A.

Afiliación

Coombes ID; Department of Pharmacy, Royal Brisbane and Women's Hospital.
Legg A; Department of Pharmacy, University of Queensland, Brisbane.
Patterson T; COVID-19 Medicines, Pharmacy Planning and Response Group.
Kelly T; Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane.
Henderson A; COVID-19 Clinical Therapeutic Guideline Working Group.
Roberts JA; Department of Pharmacy, Logan Hospital, Brisbane.

Aust Prescr ; 45(2): 67-68, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35592373

Palabras clave

COVID-19; SARS-CoV-2; molnupiravir; nirmatrelvir/ritonavir; quality use of medicines

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Aust Prescr Año: 2022 Tipo del documento: Article Pais de publicación: Australia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google